Global clinical trial shows improved survival rates for common childhood leukemia
Dec 18, 2024
1 min read
Early study results were so promising that the trial closed early, with findings published in the New England Journal of Medicine showing a striking 61% reduction in the risk of B-ALL relapse or death for those who received both chemotherapy and blinatumomab.